Skip to main content
Premium Trial:

Request an Annual Quote

Paired Ends: Bob Holland, Dan Quayle

Premium

Oxford Gene Technology has named Bob Holland as its new chief medical officer.

Holland previously was VP and head of AstraZeneca's Personalized Healthcare and Biomarkers division, which he helped create.

In his new role, Holland will lead clinical affairs across OGT's business areas, including working with R&D and commercial teams to develop clinical development programs to expand the company's next-generation sequencing and microarray cancer profiling solutions, and its biomarker programs for prostate and colorectal cancers.


Former US Vice President Dan Quayle has been elected to the TGen Foundation's board of directors.

The foundation is the fundraising branch of the Translational Genomics Research Institute.

Quayle is chairman of the private equity firm Cerberus Global Investments. He is a resident of Paradise Valley, Ariz., and he grew up in Phoenix.

The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.